Abstract 220P
Background
Radiation oral mucositis (radiotherapy-induced oral mucositis, RIOM), as one of the common complications during radiotherapy, is difficult to avoid and predict. Severe RIOM will reduce the quality of life of patients and affect the normal progress of diagnosis and treatment. Early detection and early intervention is very important to reduce the incidence of RIOM, but at present, the sensitivity and specificity of clinical indicators for the occurrence and development of radiation stomatitis are poor, so it is necessary to study further the treatment factors and predictive indicators of radiation stomatitis. It has been found that oral flora are closely related to the progression of radiation oral mucositis.
Methods
27 postoperative patients with oral squamous cell carcinoma were enrolled in the study. The cotton swab samples of oral buccal mucosa before and after radiotherapy were collected. The diversity, species differences and marker species of the oral microbial community were determined by 16 S rRNA sequencing and metagenome sequencing.
Results
Compared with the pre-radiotherapy group, the composition of oral flora in the radiotherapy group and the post-radiotherapy group changed, and the community diversity decreased significantly. The richness of different flora was different. In terms of genera, there was a difference in the richness of Haemophilus during radiotherapy, after radiotherapy and before radiotherapy, and the number of different bacteria was positively correlated with the time of radiotherapy. At the species level, the diversity of Streptococcus pneumoniae and Haemophilus haemolyticus increased significantly after radiotherapy. In terms of functional distribution, based on KEGG and CAZymes database, there were differences in functional distribution between the two groups of oral flora.
Conclusions
Radiotherapy can change the species structure and composition of oral flora and reduce community diversity. Streptococcus pneumoniae and Haemophilus haemolyticus may be related to the occurrence and development of radiation oral mucositis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session